Sonoma Pharmaceuticals Stock Performance
| SNOA Stock | USD 3.48 0.14 3.87% |
On a scale of 0 to 100, Sonoma Pharmaceuticals holds a performance score of 6. The entity has a beta of -0.33, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Sonoma Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Sonoma Pharmaceuticals is likely to outperform the market. Please check Sonoma Pharmaceuticals' semi variance, and the relationship between the maximum drawdown and accumulation distribution , to make a quick decision on whether Sonoma Pharmaceuticals' existing price patterns will revert.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Sonoma Pharmaceuticals are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat inconsistent basic indicators, Sonoma Pharmaceuticals sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (3.87) | Five Day Return 4.19 | Year To Date Return 29.85 | Ten Year Return (99.51) | All Time Return (99.99) |
Last Split Factor 1:20 | Dividend Date 2019-06-20 | Last Split Date 2024-08-30 |
1 | Williams-Sonoma Stock Falls Amid Market Uptick What Investors Need to Know | 02/11/2025 |
2 | Williams-Sonoma, Inc. Receives 172.34 Average Price Target from Analysts | 02/24/2025 |
3 | Sonoma Valley Girls Soccers Hopes Dashed In Round 1 Playoff Loss | 03/07/2025 |
4 | Williams-Sonoma, Inc. announces release date for fourth quarter results Wednesday, March 19th, 2025 | 03/14/2025 |
5 | Wine Expert Reveals Californias Hidden Sonoma County Gems | 03/17/2025 |
6 | Williams-Sonoma Q4 2025 Earnings Preview | 03/18/2025 |
7 | Why Williams-Sonoma Stock Is Trading Lower Today | 03/19/2025 |
8 | Williams-Sonoma Reports Strong Q4 Earnings and Provides Guidance Despite 1 percent Revenue Dip | 03/20/2025 |
9 | Why Is Williams-Sonoma Facing Challenges In The Home Goods Market | 03/21/2025 |
| Begin Period Cash Flow | 3.8 M |
Sonoma |
Sonoma Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 273.00 in Sonoma Pharmaceuticals on December 24, 2024 and sell it today you would earn a total of 75.00 from holding Sonoma Pharmaceuticals or generate 27.47% return on investment over 90 days. Sonoma Pharmaceuticals is currently generating 0.6376% in daily expected returns and assumes 7.3807% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Sonoma, and 88% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sonoma Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sonoma Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sonoma Pharmaceuticals, and traders can use it to determine the average amount a Sonoma Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0864
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | SNOA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.38 actual daily | 65 65% of assets are less volatile |
Expected Return
| 0.64 actual daily | 12 88% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 6 94% of assets perform better |
Based on monthly moving average Sonoma Pharmaceuticals is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sonoma Pharmaceuticals by adding it to a well-diversified portfolio.
Sonoma Pharmaceuticals Fundamentals Growth
Sonoma Stock prices reflect investors' perceptions of the future prospects and financial health of Sonoma Pharmaceuticals, and Sonoma Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sonoma Stock performance.
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | (0.27) % | ||||
| Operating Margin | (0.29) % | ||||
| Current Valuation | 457.39 K | ||||
| Shares Outstanding | 1.62 M | ||||
| Price To Earning | 2.57 X | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 0.40 X | ||||
| Revenue | 12.73 M | ||||
| Gross Profit | 5.03 M | ||||
| EBITDA | (4.53 M) | ||||
| Net Income | (4.83 M) | ||||
| Cash And Equivalents | 5.59 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 608 K | ||||
| Debt To Equity | 0.12 % | ||||
| Current Ratio | 3.05 X | ||||
| Book Value Per Share | 3.01 X | ||||
| Cash Flow From Operations | (2.4 M) | ||||
| Earnings Per Share | (2.26) X | ||||
| Market Capitalization | 5.62 M | ||||
| Total Asset | 14.74 M | ||||
| Retained Earnings | (194.35 M) | ||||
| Working Capital | 8.83 M | ||||
| Current Asset | 12.89 M | ||||
| Current Liabilities | 3.55 M | ||||
About Sonoma Pharmaceuticals Performance
By analyzing Sonoma Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Sonoma Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sonoma Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sonoma Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 111.79 | 64.47 | |
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.91) | (0.86) |
Things to note about Sonoma Pharmaceuticals performance evaluation
Checking the ongoing alerts about Sonoma Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sonoma Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sonoma Pharmaceuticals is way too risky over 90 days horizon | |
| Sonoma Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Sonoma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 12.73 M. Net Loss for the year was (4.83 M) with profit before overhead, payroll, taxes, and interest of 5.03 M. | |
| Sonoma Pharmaceuticals currently holds about 5.59 M in cash with (2.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Latest headline from kalkinemedia.com: Why Is Williams-Sonoma Facing Challenges In The Home Goods Market |
- Analyzing Sonoma Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sonoma Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Sonoma Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sonoma Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sonoma Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sonoma Pharmaceuticals' stock. These opinions can provide insight into Sonoma Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sonoma Stock analysis
When running Sonoma Pharmaceuticals' price analysis, check to measure Sonoma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sonoma Pharmaceuticals is operating at the current time. Most of Sonoma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Sonoma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sonoma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Sonoma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |